KR20200018383A - 천연 복합 호르몬 대체 제형 및 요법 - Google Patents

천연 복합 호르몬 대체 제형 및 요법 Download PDF

Info

Publication number
KR20200018383A
KR20200018383A KR1020197019625A KR20197019625A KR20200018383A KR 20200018383 A KR20200018383 A KR 20200018383A KR 1020197019625 A KR1020197019625 A KR 1020197019625A KR 20197019625 A KR20197019625 A KR 20197019625A KR 20200018383 A KR20200018383 A KR 20200018383A
Authority
KR
South Korea
Prior art keywords
estradiol
progesterone
subject
max
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197019625A
Other languages
English (en)
Korean (ko)
Inventor
줄리아 엠. 아마디오
브라이언 에이. 버닉
세바스찬 미어킨
Original Assignee
쎄러퓨틱스엠디, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쎄러퓨틱스엠디, 인코퍼레이티드 filed Critical 쎄러퓨틱스엠디, 인코퍼레이티드
Publication of KR20200018383A publication Critical patent/KR20200018383A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197019625A 2016-12-05 2018-02-02 천연 복합 호르몬 대체 제형 및 요법 Ceased KR20200018383A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (1)

Publication Number Publication Date
KR20200018383A true KR20200018383A (ko) 2020-02-19

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019625A Ceased KR20200018383A (ko) 2016-12-05 2018-02-02 천연 복합 호르몬 대체 제형 및 요법

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020504093A (cg-RX-API-DMAC7.html)
KR (1) KR20200018383A (cg-RX-API-DMAC7.html)
CN (1) CN110290793A (cg-RX-API-DMAC7.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC7.html)
IL (1) IL267023A (cg-RX-API-DMAC7.html)
MX (1) MX2019006513A (cg-RX-API-DMAC7.html)
RU (1) RU2019115913A (cg-RX-API-DMAC7.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR100562A1 (es) * 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC7.html) 2021-03-19
MX2019006513A (es) 2019-08-14
JP2020504093A (ja) 2020-02-06
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
Genazzani et al. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice
Archer et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
Svigos et al. A practical approach to the diagnosis and management of classic lichen planopilaris
Sibai et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™)
Modelska et al. Tibolone for postmenopausal women: systematic review of randomized trials
Shifren et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study
Murphy et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
Casper et al. A historical perspective of aromatase inhibitors for ovulation induction
Simon et al. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms
Mattsson et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms
Skouby et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel
Ettinger Personal perspective on low-dosage estrogen therapy for postmenopausal women
CA2644913A1 (en) Methods for prevention and treatment of conditions arising from local estrogen deficiency
KR20170005819A (ko) 천연 복합 호르몬 대체 제형 및 요법
Sood et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial
Archer Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women
Gast et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women
JP2021525266A (ja) 頸部障害の処置のためのロピナビルおよびリトナビル
Ashraf et al. The experience of a tertiary unit on the clinical phenotype and management of hypogonadism in female adolescents and young adults with transfusion dependent thalassemia
Hedrick et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women
Elkinson et al. Ospemifene: first global approval
Looby et al. Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial
JP2020504093A (ja) 天然配合ホルモン補充製剤及び治療法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210129

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221004

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230405

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221004

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I